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Abstract
Background: A high incidence of cardiovascular (CV) risk factors has been reported in adults with Williams-Beuren
syndrome (WS). However, the prevalence of these factors in children and adolescents with WS is unknown. Therefore, the
purpose of this study was to evaluate the prevalence of CV risk factors in these patients.
Methods: Thirty-two WS patients aged <18 years were enrolled in the study. Oxidized low-density lipoprotein levels
(n = 32), oral glucose tolerance test results (n = 20), plasma renin and aldosterone levels (n= 31), 24-h ambulatory blood
pressure (ABP; n = 24), carotid artery intima-media thickness (IMT; n = 15), and brachial artery flow-mediated dilatation
(FMD; n = 15) were measured and analyzed.
Results: The lipid profile revealed hypercholesterolemia in 22 % and elevated oxidized low-density lipoprotein levels in
94 % of the patients. Glucose metabolism abnormalities were found in 70 % of the patients. Insulin resistance was
observed in 40 % of the patients. High plasma renin and aldosterone levels were detected in 45 and 39 % of the patients,
respectively. A mean systolic blood pressure above the 90th percentile was noted in 29 % of patients. High IMT
(>0.65 mm) and low FMD (<9 %) were detected in 80 and 73 % of patients, respectively.
Conclusion: In patients with WS, CV risk factors are frequently present from childhood. In children with WS, screening
tests for the early detection of CV risk factors and long-term follow-up are required to determine whether long-term
exposure to these factors increases the risk for CV events in adulthood.
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Background
Williams-Beuren syndrome (WS) was first described in
1961 by Williams et al. [1]. They reported four patients
with supravalvular aortic stenosis (SVAS), mental retard-
ation, and characteristic facial features. At present, WS
is recognized as a congenital developmental disorder
involving the connective tissue and central nervous
system, and it is accompanied by various characteristic
facial features. The syndrome is characterized by growth
delay, mental retardation with typical neurobehavioral
profile [2], cardiovascular (CV) abnormalities, hyperten-
sion, hypercholesterolemia, hypothyroidism, and occasional
infantile hypercalcemia. In 1993, Ewart et al. [3] reported
that haploinsufficiency of multiple genes, including micro-
deletions of the elastin gene locus at 7q11.23, contribute to
the phenotypic features of WS. Loss of elastin function is
responsible for the associated CV abnormalities [4]. In adult
WS patients, CV risk factors such as diabetes mellitus,
hypertension, and hyperlipidemia are frequently present [5].
The prevalence of these risk factors among children with
WS remains unknown; however, we hypothesize that they
are present from a young age. A high prevalence of CV risk
factors in childhood would likely contribute to CV events
during adulthood. The purpose of this study was to
evaluate the incidence of such factors, including hyper-
cholesterolemia, impaired glucose tolerance, high
blood pressure, renin-angiotensin-aldosterone (RAA)
activation, intima-media thickness (IMT) of the carotid
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artery, and endothelial dysfunction in children and
adolescents with WS; this is an important step in the
prevention of future CV events in WS patients.
Methods
We studied 32 WS patients aged <18 years. Fluorescence
in situ hybridization (FISH) was performed using the
following 6 probes: PAC537N8 (WSTF and FZD9),
BAC27H2 (STX1A), WSCR (ELN), PAC 117G9 (LIMK1),
BAC363B4 (RFC2, CYLN2), and BAC1184P14 (GTF2I),
which included 8 genes for detecting microdeletions on
chromosome 7q11.23, as previously reported [6]. A typ-
ical deletion was revealed in 26 patients, and an atypical
shorter deletion was discovered in 6 (Fig. 1). The following
laboratory measurements were obtained: (1) a plasma lipid
profile that included oxidized low-density lipoprotein
(oxLDL) (n = 32) and lipoprotein-a (Lipo(a); n = 32); (2)
glucose levels (via the oral glucose tolerance test (OGTT;
n = 20); (3) plasma renin and aldosterone levels (n = 31);
(4) 24-h ambulatory blood pressure (ABP; n = 24); (5)
carotid artery IMT (n = 15); and (6) brachial artery
flow-mediated dilatation (FMD; n = 15). All biochemical
measurements in this study were performed using com-
mercially available kits. The OxLDL and malondialde-
hyde-modified low-density lipoprotein (MDA-LDL) levels
were measured (oxLDL, Kyowa Medics, Japan; n = 13 and
MDA-LDL enzyme-linked immunosorbent assay, SRL,
Japan; n = 19). A high oxLDL level was defined as oxLDL
>7 U/L (normal: <6.9 U/L) or MDA-LDL >38.3 U/ L (nor-
mal: <38.2 U/L) in patients aged <18 years. Lipo(a) was also
measured (SRL, Japan), and a high Lipo(a) level was de-
fined as a level of >40 mg/ dL (normal: <39 mg/dL). The
standard 2-h OGTT was performed in 20 patients with no
history of diabetes, with the results classified according to
the guidelines of the American Diabetes Association. Im-
paired fasting glucose level was defined as a glucose level
of 100–125 mg/dL, and impaired glucose tolerance was de-
fined as a plasma glucose level of 140–199 mg/dL 2 h
Fig. 1 The chromosome 7q11.23 microdeletion was associated with the Williams-Beuren syndrome phenotypes in all subjects. Overall, 26 of 32
patients (82 %) showed the typical deletion responsible for Williams-Beuren syndrome (denoted as A), and 6 patients showed atypical deletions
shorter than A (B, n = 2; C, n = 3; and D, n = 1)
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after OGTT. Type 2 diabetes was defined as a fasting
glucose level of ≥126 mg/dL or a 2-h plasma glucose level
of >200 mg/dL [7]. The homeostasis model assessment in-
sulin resistance index (HOMA-IR) was also measured, with
insulin resistance defined as HOMA-IR >2. Impaired insu-
lin secretion was defined as an insulinogenic index <0.4.
Plasma levels of active renin were measured (PRA, SRL,
Japan, respectively), and elevated renin levels were defined
as levels > 3 pg/mL (normal range: 0.3–2.9 pg/mL).
Plasma levels of aldosterone were measured (Aldoster-
one RIA kit II; Dinabot, Japan; n = 15 or SPAC-S Al-
dosterone Kit; TFB, Japan; n = 17). Elevated aldosterone
levels were defined as levels >15 ng/dL (normal range:
2.2–14.9 ng/dL) and >159 pg/mL (normal range: 29.9–
158 pg/mL) as measured using the SPAC-S aldosterone
kit and RIA kit II, respectively. On the basis of ABP, high
blood pressure (BP) was defined as a mean daytime BP
above the 90th percentile corrected by sex, age, and
height, as previously reported [8].
For IMT assessment, both common carotid arteries were
measured in the longitudinal plane from the level of the
clavicles to the carotid bifurcation, as previously reported
[9]. Abnormal thickening was defined as IMT> 0.65 mm in
individuals aged < 18 years [9–11]. FMD was measured in
the right brachial artery after sublingual administration of
nitroglycerin, in order to determine the extrinsic nitric
oxide donor (nitroglycerin)-induced dilatation (NID), as
previously reported [12]. Low FMD was defined as FMD<
9 %, and low NID was defined as FMD< 12 %. Ethical
approval for this study was granted by the institutional
review board of the Tokyo Women’s Medical University
Hospital, Japan. Informed consent was obtained from
the participants themselves or their parents in the case
of children aged <16 years.
Statistical analysis
Data are expressed as median (range) or mean ± standard
deviation. Comparisons between the two groups were per-
formed using the unpaired t-test or Mann–Whitney U-test.
Pearson’s correlation coefficient was used to assess the
associations between the two groups. Values were consid-
ered significantly different at p < 0.05. All analyses were
performed using the JMP statistical software (version 11;
SAS Institute, Cary, NC).
Results
In the 32 WS patients, the median age of the subjects was
9.1 years (range, 1.3–17.9 years). The male: female ratio
was 1:1.5, and the median height, body weight, and body
mass index (BMI) were 122 cm (range, 78–147 cm), 25 kg
(range, 6–41 kg) and 15.4 (range, 10.0–22.8), respectively.
A BMI > 22 was observed in only 1 patient (3 %).
Cardiovascular abnormalities
CV abnormalities were observed in 29 out of 32 patients
(91 %). Among these, 24 patients had SVAS. The details of
CV abnormalities are shown in Table 1. Five patients
underwent surgical intervention for these abnormalities.
Repair of the SVAS and ligation of patent ductus arterio-
sus had been performed previously in 4 and 1 patients,
respectively. At the time of the study, no patient showed
SVAS with an estimated pressure gradient of >50 mm Hg
between the left ventricle and ascending aorta, as mea-
sured by echocardiography or cardiac catheterization. One
patient had moyamoya disease.
Lipid profile
The results of lipid profile testing are shown in Table 2.
Overall, 92 % (23/25) of the patients without hypercholes-
terolemia had high levels of oxLDL. The median level of
total cholesterol, oxLDL, MDA-LDL, Lipo(a), high-
density lipoprotein-cholesterol, and triglycerides were
166 mg/dL (range, 86–236 mg/dL),12.6 U/L (range,
7.5–46.6 U/L), 62.6 U/L (range, 28.6–116.0 U/L), 11 U/L
(range, 3–99 U/L), 62 mg/ dL (range, 34–96 mg/dL), and
51 mg/dL (range, 33–116 mg/dL), respectively. There was
no significant correlation between oxLDL levels and BMI.
The results for the various parameters are summarized in
Table 3.
Impaired glucose metabolism
In this study, 14 patients demonstrated impaired glucose
tolerance. Four and 10 of these patients were subse-
quently diagnosed with diabetes and impaired glucose
tolerance, respectively. The median fasting blood sugar
and insulin levels were 94 mg/dL (range, 80–103 mg/dL)
Table 1 Summary of the cardiovascular abnormalities of the 32
patients
Number
SVAS alone 7
SVAS with MVP 6
SVAS with pulmonary stenosis 5
SVAS with ventricular septal defect 2
SVAS with MVP and PAPVR 1
SVAS with MVP and pulmonary stenosis 1
SVAS with coarctation of the aorta 1
SVAS with a bicuspid aortic valve 1
MVP alone 3
MVP with patent ductus arteriosus 1
Pulmonary stenosis 1
None 3
Total number = 32
SVAS: supravalvular aortic stenosis, MVP: mitral valve prolapse, PAPVR: partial
anomalus pulmonary venous return
Takeuchi et al. BMC Pediatrics  (2015) 15:126 Page 3 of 9
and 7.5 μU/mL (range, 0.2–13.7 μU/mL), respectively.
The insulinogenic index was 0.8 (range, 0.2–1.2) and
the HOMA-IR was 1.8 (range, 0.03–3.1). The glycated
hemoglobin level was <6.2 % in all patients, with a me-
dian level of 4.8 % (range, 4.6–5.0 %). A BMI of > 22
was observed in only 1 patient.
Plasma renin and aldosterone activation
The median plasma renin level was 2.6 pg/mL (range,
0.3–13.0 pg/mL). The median plasma aldosterone level
measured using the RIA kit II was 10.1 ng/dL (range,
5.2–22.9 ng/dL) and that measured using the SPAC-S kit
was 165 pg/mL (range, 57.3–393 pg/mL).
Ambulatory blood pressure monitoring
The median daytime BP in all subjects was 116 mm Hg
(range, 100–131 mm Hg). The median daytime BP was
126 mm Hg (range, 120–147 mm Hg) and 109 mm Hg
(range, 103–119 mm Hg) in the hypertensive and non-
hypertensive groups, respectively. The BMI was not
significantly different between the hypertensive and
nonhypertensive groups (15.8 [14.4–18.0] vs. 16.1
[13.4–22.8], respectively).
IMT of the carotid artery
The median IMT of the right and left carotid artery was
0.73 mm (range, 0.50–0.90 mm) and 0.71 mm (range,
0.50–0.90 mm), respectively. A high IMT in at least one
carotid artery (>0.65 mm) was observed in 80 % of patients
(12/15). The median IMT of the right carotid artery was
0.70 mm (range, 0.60–0.79 mm) and 0.73 mm (range,
0.50–0.90 mm) in the hypertensive and the nonhyperten-
sive groups, respectively. The median IMT of the left
carotid artery was 0.70 mm (range, 0.60–0.89 mm) and
0.71 mm (range, 0.50–0.90 mm) in the hypertensive and
nonhypertensive groups, respectively. There were no sig-
nificant differences in IMT between the hypertensive and
nonhypertensive groups. There were also no significant
correlations between age and IMT (left IMT: R = −0.02;
right IMT: R = −0.04) or SVAS pressure gradients
estimated using echocardiography and IMT (R = 0.3). The
relationship between IMT of the carotid artery and age is
summarized in Fig. 2a and 2b.
FMD of the brachial artery
The median FMD was 5.6 % (range, 0–18.2 %), and low
FMD (<9 %) was detected in 73 % (11/15) of the patients.
The median level of NID was 16 % (range, 7.1–25.9 %), and
low NID (<12 %) was observed in 13 % (2/15) of the
patients. The mean FMD was 4.3 % ± 3.2 % and 7.4 % ±
1.6 % in the hypertensive and nonhypertensive groups, re-
spectively. The mean FMD between groups was not
significantly different. There were also no significant
correlations between BMI and FMD (R = 0.02), age
and FMD (R = −0.13), or age and NID (R = −0.15).
The relationship between FMD or NID of the bra-
chial artery and age is summarized in Fig. 3a and 3b.
Hypertension
There were no differences in any of the study measure-
ments between the hypertensive and non-hypertensive
groups.
Deletions
Results of the chromosome 7q11.23 microdeletion
associated with the phenotypes in all WS patients are
demonstrated in Fig. 1. Differences in the various pa-
rameters between the WS patients and the typical and
atypical deletions are summarized in Table 4. Plasma
renin and aldosterone levels measured by SPAC-S in pa-
tients with typical deletions (n = 26) were higher com-
pared to those in patients with atypical deletions (n = 6).
There were no significant differences in lipid profiles,
impaired glucose metabolism, hypertension, IMT, and
Table 2 Summary of lipid profile test
Number (Percentage)
Lipid profile (n = 32)
Hypercholesterolemia 7 (22 %)
High oxidized LDL 30 (94 %)
High Lipo (a) 6 (19 %)
Hypertriglyceridemia 1 (3 %)
Low high-density lipoprotein cholesterol 2 (6 %)
LDL: low-density lipoprotein
Table 3 Summary of the results of various parameters
Number (Percentage)
Glucose tolerance (n = 20)
Impaired fasting glucose 2 (10 %)
Impaired glucose tolerance or DM by OGTT 14 (70 %)
Insulin resistance (HOMA-IR>2) 8 (40 %)
Impaired insulin secretion 3 (15 %)
Renin-aldosterone system (n= 31)
Increased plasma renin level 14 (45 %)
Increased plasma aldosterone 12 (39 %)
Ambulatory blood pressure monitoring (n=24)
High blood pressure >90 percentile 7 (29)
Carotid artery ultrasound (n=15)
Increased IMT (>0.65 mm) 12 (80 %)
Endothelial dysfunction (n=15)
FMD <9 % 11 (73 %)
NG-induced dilatation <12 % 2 (13 %)
OGTT: oral glucose tolerance test, DM: diabetes mellitus, HOMA-IR: homeostasis
model assessment insulin resistance, IMT: intima-media thickness of the carotid
artery, FMD: flow-mediated dilatation of the brachial artery, NG: nitroglycerin
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endothelial function between patients with typical dele-
tions and those with atypical deletions.
Discussion
Decreased elastin function is known to be the under-
lying etiology for the cardiovascular lesions found in
WS [10, 13–16]. In adult patients, a high prevalence of
CV risk factors such as diabetes, hypertension, and
hypercholesterolemia has been reported [5, 17–19].
However, the prevalence of such risk factors in children
with WS has not been well studied. Risk stratification
in children and adolescents is important, because a
clear translation of CV risk factors in children into
adulthood is expected to increase the incidence of
future CV events [20]. As part of a holistic molecular
genetic medicine approach [21] in this study, we evalu-
ated the incidence of CV risk factors, including im-
paired glucose intolerance, hyperlipidemia, an activated
renin-aldosterone system, endothelial dysfunction, and
high IMT among children with WS.
Hyperlipidemia and impaired glucose tolerance
In our study, 22 % of the patients had hypercholesterol-
emia. Interestingly, 92 % (22/25) of the patients without
hypercholesterolemia demonstrated elevated levels of
oxLDL. Oxidation of LDL is believed to be important in
the development of early atherosclerosis, and oxLDL
possesses several biologic properties that may promote
atherogenesis [22, 23]. The OGTT results revealed that
70 % of the patients had impaired glucose tolerance or
diabetes, which is consistent with the findings of previous
studies on adult WS [5, 17–19, 24]. In this study, the high
prevalence of elevated HOMA-IR revealed that hidden in-
sulin resistance is present from childhood in WS patients.
Both insulin resistance and an increased production of
oxLDL may be associated with the progression of athero-
sclerosis in WS. Conversely, the elastin peptide that is de-
rived from the degradation of elastin induces the
oxidation of LDL by phagocytic cells and thereby pro-
motes the initiation and progression of the atherosclerotic
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process [25]. Although obesity is strongly associated with
hypercholesterolemia and insulin resistance in children as
well as adults, only 1 patient in this study had a BMI
of >22. The abnormal lipid or glucose metabolism in
the rest of the children with WS was not associated
with a high BMI. A close relationship between obesity
and abnormal lipid/glucose metabolism is not possible
with WS. This finding suggests that conditions other than
obesity are involved in the high prevalence of CV risk fac-
tors in children with WS. Glucose dysregulation is caused
by the hemizygosity of syntaxin-1A, a gene located in the
WS chromosome region that is believed to be the prime
candidate involved in insulin release [24].
Activation of the RAA system and hypertension
Activation of the RAA system is associated with CV
events and progression of arteriosclerosis [26]. In the
current study, hypertension and activation of the RAA
system were commonly found in the WS patients
(Table 1), but there were no significant differences in the
renin and aldosterone levels between the hypertensive
and nonhypertensive groups. The etiology of hyperten-
sion among these patients appears to be multifactorial
and potentially involves elastin haploinsufficiency, neu-
trophil cytosolic factor 1 hemizygosity [27], reduced
nicotinamide adenosine dinucleotide phosphate-oxidase-
mediated oxidative stress [28], an activated RAA system,
Table 4 Differences in various clinical and laboratory parameters between the typical and atypical deletion groups
n: number, BMI: body mass index, T-cho: total cholesterol, TG : triglyceride, HDL: high density lipoprotein, MDA- LDL: malondialdehyde-modified, LDL, OGTT: oral glucose
tolerance test, GI glucose intolerance, DM: diabetes mellitus, HOMA-R : homeostasis model assessment insulin resistance, FBS: fasting blood sugar, MT: flow- mediated
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and renovascular disease. In this study, patients with
typical deletions exhibited a higher degree of RAA sys-
tem activity than did patients with atypical deletions.
However, the reason behind the high RAA system activ-
ity in the typical deletions group remains unclear.
Whether microdeletion on chromosome 7q11.23 leads to
RAA system activation is also unclear. The precise role
of the RAA system in WS should therefore be clarified
in future studies.
Brachial artery flow-mediated dilatation and carotid artery
intima-media thickness
In this study, WS patients exhibited high carotid artery
IMT, as previously reported [9]. An autopsy of a patient
with WS revealed thickened medial tissue with elastic
disorganization and a prominence of smooth muscle,
not only in the arterial wall of the ascending aorta but
also in the arteries of the lungs, kidneys, mesentery, and
brain [6, 29]. Generalized arterial wall thickening with
secondary lumen narrowing has also been observed in
WS [10]. Therefore, this feature is considered a general-
ized elastin arteriopathy that presents in WS. Thickened
medial tissue is thought to be primarily associated with
high IMT in these patients; however, ultrasonography
cannot differentiate between intimal atherosclerosis and
medial hypertrophy.
Low FMD was also observed in the patients in this
study. The current study is the first to demonstrate a
high prevalence of impaired endothelial function associ-
ated with WS. FMD was considered an indicator of vas-
cular endothelial function. Juonala et al. [12] reported
that thickened IMT and low FMD are related to CV
events. Even in children with diabetes mellitus, obesity,
and hyperlipidemia, low FMD reflects impaired endothe-
lial function from early childhood [30–34], and long-
term exposure to such risk factors is associated with the
development of atherosclerosis later in life [30]. The
overall incidence of hypercholesterolemia and hyperten-
sion in Japanese school-age children has been reported
to be 7 and 1 %, respectively [35], lower than the rates
observed in our study. Although the number of patients
enrolled in our study was small, the results strongly sug-
gest that exposure to CV risk factors is present from
childhood in patients with WS.
Diet and exercise intervention for obese children can
reverse the pro-atherosclerotic inflammatory process
and preserve vascular function [36]. Good familial sup-
port in order to avoid stress, which affects both mental
and metabolic states, as well as the appropriate adminis-
tration of drugs and supplements, may also be useful
against the pro-atherosclerotic process in WS [16]. Min-
oxidil, glucocorticoids, retinoids, vitamin E and C, and
matrix metalloproteinase inhibitors have the potential to
upregulate elastin production or prevent its degradation
[16, 25, 37–40]. Nutritional supplements such as β-
aminopropionitrile (contained in certain legumes), dill
extract, and tannic acid may also be effective in prevent-
ing elastin arteriopathy [16, 41, 42]. As part of a holistic
approach for the management of patients with WS, we
encourage patients to follow a traditional low-fat Japanese
diet including rice, seaweed, wheat, barley, beans, fish, and
vegetables and avoid other animal protein. We also rec-
ommend supplementation with vitamin C and E and good
familial support. Two patients from a similar study experi-
enced a decrease in IMT and an improvement in FMD as
a result of this regimen [21].
Conclusion
CV risk factors such as hypertension, impaired glucose
tolerance, hyperlipidemia, and high IMT are highly
prevalent in children with WS. Long-term exposure to
these factors may accelerate the development of CV dis-
ease in adulthood. WS is a multisystem disorder that re-
quires long-term follow-up, because WS is diagnosed
during childhood in most cases. Health care supervisors
and pediatricians, who care for children with WS need
to be aware of these findings [43]. Screening tests for the
early detection of CV risk factors such as abnormal
lipid/glucose metabolism unrelated to obesity and long-
term follow-up in WS patients could be helpful for pre-
venting CV events in adulthood. Further studies are also
needed to clarify the etiology of the various risk factors
influencing CV events in these patients.
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